A House Republican plan to tackle drug shortages focuses on increased reimbursement to shore up the US supply chain, relying on manufacturer’s good will rather than mandates to use those additional resources to prevent and mitigate drug shortages.
All Carrots, No Sticks: House Republican Drug Shortage Plan Ups Reimbursement But Lacks Supply, Quality Commitments
New Republican House Energy and Commerce shortage plan is seen as reasonable starting point, though in need of much strength to address root causes of supply troubles. Most changes apply to generic drugs, but a few could impact brands.
More from Legislation
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Republican congressional staffers could bring a wealth of experience and strong contacts with key legislators to the FDA ahead of the next user fee reauthorization process. But will Health and Human Services Department leadership interfere?
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.